TALi Digital Valuation

Is TD1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TD1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TD1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TD1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TD1?

Key metric: As TD1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TD1. This is calculated by dividing TD1's market cap by their current revenue.
What is TD1's PS Ratio?
PS Ratio	33.8x
Sales	AU$146.23k
Market Cap	AU$4.94m

TD1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	19.3x
Enterprise Value/EBITDA	-2.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TD1's PS Ratio compare to its peers?

The above table shows the PS ratio for TD1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.9x
ICR Intelicare Holdings	17.2x	n/a	AU$4.9m
TRI TrivarX	7.7x	n/a	AU$6.9m
GLH Global Health	0.9x	n/a	AU$7.8m
VFX Visionflex Group	1.7x	n/a	AU$11.7m
TD1 TALi Digital	33.8x	n/a	AU$4.9m

Price-To-Sales vs Peers: TD1 is expensive based on its Price-To-Sales Ratio (33.8x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does TD1's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
MDR MedAdvisor	1.3x	13.4%	US$103.80m
DOC Doctor Care Anywhere Group	0.3x	6.3%	US$15.72m
IME ImExHS	0.7x	20.5%	US$10.51m
VFX Visionflex Group	1.7x	n/a	US$7.58m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: TD1 is expensive based on its Price-To-Sales Ratio (33.8x) compared to the Global Healthcare Services industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is TD1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TD1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	33.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TD1's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$131.3m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.11

5.2%

39.9%

Doctor Care Anywhere Group

AU$23.8m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.064

-5.9%

36.2%

SDI

AU$131.3m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.10

2.3%

45.7%